Frank M. Torti's most recent trade in Roivant Sciences Ltd was a trade of 40,310 Common Shares done at an average price of $35.4 . Disclosure was reported to the exchange on June 30, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd | Frank M. Torti | President and Vant Chair | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.39 per share. | 30 Jun 2026 | 40,310 | 13,536,202 | - | 35.4 | 1,426,571 | Common Shares |
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2026 | 174,189 | 1,009,228 (1%) | 0% | 0 | Common Stock | |
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2026 | 88,325 | 88,325 | - | - | Stock Option (right to buy) | |
| Roivant Sciences Ltd | Frank M. Torti | President and Vant Chair | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.70 per share. | 31 Mar 2026 | 160,035 | 13,576,512 | - | 27.7 | 4,432,970 | Common Shares |
| Roivant Sciences Ltd | Frank M. Torti | President and Vant Chair | Grant, award, or other acquisition of securities at price $ 22.45 per share. | 23 Dec 2025 | 175,380 | 13,911,927 | - | 22.5 | 3,937,281 | Common Shares |
| Roivant Sciences Ltd | Frank M. Torti | President and Vant Chair | Gift of securities by or to the insider at price $ 0.00 per share. | 23 Dec 2025 | 110,489 | 13,736,547 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Frank M. Torti | President and Vant Chair | Other type of transaction at price $ 22.47 per share. | 23 Dec 2025 | 64,891 | 13,847,036 | - | 22.5 | 1,458,101 | Common Shares |
| Roivant Sciences Ltd | Frank M. Torti | President and Vant Chair | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jul 2025 | 11,900,000 | 13,736,547 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Frank M. Torti | President and Vant Chair | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jul 2025 | 1,836,547 | 1,836,547 | - | 0 | Common Shares | |
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 199,365 | 835,039 (1%) | 0% | 0 | Common Stock | |
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 93,599 | 93,599 | - | - | Stock Option (right to buy) | |
| Arbutus Biopharma Corp | Frank M. Torti | Director | 23 May 2024 | 67,000 | 67,000 | - | - | Stock Option (Right to Buy) | ||
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 120,400 | 635,674 (1%) | 0% | 0 | Common Stock | |
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 50,167 | 50,167 | - | - | Stock Option (right to buy) | |
| Arbutus Biopharma Corp | Frank M. Torti | Director | 24 May 2023 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | ||
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2023 | 158,292 | 158,292 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2023 | 121,916 | 515,274 (0%) | 0% | 0 | Common Stock | |
| Immunovant Inc | Frank M. Torti | Director | Purchase of securities on an exchange or from another person at price $ 5.81 per share. | 29 Sep 2022 | 20,000 | 393,358 (0%) | 0% | 5.8 | 116,200 | Common Stock |
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2022 | 339,296 | 339,296 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2022 | 225,632 | 373,358 (0%) | 0% | 0 | Common Stock | |
| Arbutus Biopharma Corp | Frank M. Torti | Director | 25 May 2022 | 41,000 | 41,000 | - | - | Stock Option (Right to Buy) | ||
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2022 | 329,485 | 554,748 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2022 | 100,126 | 147,726 (0%) | 0% | 0 | Common Stock |